REGN vs. VRTX, BMY, SNY, GSK, ZTS, PFE, TAK, RPRX, BGNE, and CTLT
Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Zoetis (ZTS), Pfizer (PFE), Takeda Pharmaceutical (TAK), Royalty Pharma (RPRX), BeiGene (BGNE), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
Regeneron Pharmaceuticals has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.
In the previous week, Regeneron Pharmaceuticals had 7 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 21 mentions for Regeneron Pharmaceuticals and 14 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.94 beat Regeneron Pharmaceuticals' score of 0.80 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Regeneron Pharmaceuticals presently has a consensus price target of $950.35, suggesting a potential downside of 1.61%. Vertex Pharmaceuticals has a consensus price target of $417.27, suggesting a potential upside of 0.96%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.
Vertex Pharmaceuticals has a net margin of 36.68% compared to Regeneron Pharmaceuticals' net margin of 30.14%. Vertex Pharmaceuticals' return on equity of 21.91% beat Regeneron Pharmaceuticals' return on equity.
Vertex Pharmaceuticals received 58 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 75.58% of users gave Vertex Pharmaceuticals an outperform vote while only 66.52% of users gave Regeneron Pharmaceuticals an outperform vote.
84.2% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.8% of Vertex Pharmaceuticals shares are owned by institutional investors. 8.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Regeneron Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Regeneron Pharmaceuticals Competitors List
Related Companies and Tools